Core Viewpoint - The company Bibeite (688759.SH) has initiated its subscription with an issue price of 17.78 yuan per share, focusing on innovative drug development in the biopharmaceutical sector, particularly targeting major diseases such as tumors and autoimmune diseases [1] Group 1: Company Overview - Bibeite is a biopharmaceutical company that emphasizes clinical value and is dedicated to the independent research and development of innovative drugs [1] - The company has one approved breakthrough therapy drug, BEBT-908, for the treatment of r/rDLBCL, and several other products in various stages of clinical trials [1] - BEBT-908 is the first-in-class small molecule dual-target inhibitor designed for HDAC/PI3Kα, with no other similar inhibitors approved or in development in China as of June 30, 2025 [1] Group 2: Financial Performance - For the fiscal years 2022, 2023, and 2024, the company's net profits are projected to be approximately -188 million yuan, -173 million yuan, and -55.998 million yuan respectively [2] - The company is currently not profitable and anticipates significant ongoing R&D investments, which will keep R&D expenses at a high level [2] - Due to the lack of profitability, the company may not be able to distribute profits or pay cash dividends in the short term [2]

- The report tracks the recent IPO market performance, focusing on the net gains from new stock listings across the Sci-Tech Innovation Board, ChiNext, and Main Board, assuming all stocks are successfully subscribed and sold at the market average price on the first trading day, excluding lock-up restrictions[1][11][39] - The cumulative IPO net gains for A-class accounts with a scale of 2 billion reached 2.44%, while B-class accounts of the same scale achieved 2.19% as of October 24, 2025[11][39] - For larger accounts with a scale of 10 billion, the IPO net gains were significantly lower, with A-class accounts at 0.77% and B-class accounts at 0.70%[11][39] - The average first-day price increase for Sci-Tech Innovation Board stocks was 218.45%, while ChiNext stocks saw an average increase of 244.28%[1][16] - The report provides detailed calculations for theoretical IPO gains, using formulas such as: $ Full subscription quantity = Maximum subscription limit × Average offline subscription rate $ $ Full subscription gains = (First-day average price - IPO price) × Full subscription quantity $[35][39] - The highest full subscription gains among recent IPOs were achieved by United Power, Jindal Zhixin, and C Marco, with gains of 50.81, 12.58, and 11.03 million yuan respectively[35][38] - The report also includes monthly tracking of IPO gains for A-class accounts across different scales, showing a cumulative gain rate of 6.17% for 2 billion accounts since 2024, and 2.44% for 2025 alone[39][41] - Similar tracking for B-class accounts reveals a cumulative gain rate of 5.11% for 2 billion accounts since 2024, and 2.19% for 2025 alone[47][45] - The report highlights the IPO subscription process, including strategic placement, offline inquiry, and online pricing methods, with detailed statistics on subscription rates, oversubscription multiples, and effective subscription ratios for recent IPOs like Xi'an Yicai and Bibet[24][25]

Core Points - Three companies, Bibit (688759.SH), Heyuan Bio (688765.SH), and Xi'an Yicai (688783.SH), are set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, marking the first batch of new listings since the launch of the Sci-Tech Growth Tier [1] - As of now, a total of 7.58 million investor accounts have opened trading permissions for the Sci-Tech Growth Tier, representing 126% of the active accounts among existing investors [1] - Following the release of the "1+6" policy reform for the Sci-Tech Board in June, 26 new companies have been accepted for listing, with 8 of them being unprofitable [1] - The first IPO application under the fifth set of listing standards, submitted by professional institutional investor Tianomaibo, was accepted on July 31 [1] - On September 26, the second IPO project under the restarted fifth set of listing standards, Anshi Bio, was accepted [1] - Companies such as Beixin Life, unprofitable company Moer Thread, and Angrui Micro have submitted registration on July 25, September 26, and October 15, respectively, under the fifth set of standards [1] - Unprofitable company Muxi Co. passed the listing committee review on October 24 [1]

Group 1: New Stock Performance - Two new stocks were listed last week (October 20-24), with an average first-day price increase of 263.20%[2] - Both new stocks had first-day gains exceeding 100%, specifically Chao Ying Electronics at 397.60% and Marco Polo at 128.80%[2][4] - The total fundraising amount for new stocks last week increased by 1.591 billion yuan compared to the previous week[3] Group 2: Weekly and Monthly Trends - The number of new stocks listed remained unchanged at 2 for the week of October 20-24, with no first-day price drops recorded[3] - For the week of October 13-17, the average first-day price increase was 325.18%, with two stocks showing gains over 100%[4] - Monthly data shows that from October 1 to October 24, 5 new stocks were listed, raising 3.653 billion yuan, with an average first-day increase of 305.31%[10]

广州必贝特医药股份有限公司 首次公开发行股票科创板 上市公告书提示性公告 保荐人（主承销商）：中信证券股份有限公司 联席主承销商：国信证券股份有限公司 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，广州必贝特医药股份有限公司（以下简称"必 贝特"、"公司"、"本公司"或"发行人"）发行的人民币普通股股票将于 2025 年 10 月 28 日在上海证券交易所科创板上市，上市公告书全文和首次公开发行股 票的招股说明书在上海证券交易所网站（http://www.sse.com.cn）和符合中国证 监会规定条件网站（上海证券报：https://www.cnstock.com；中国证券报： https://www.cs.com.cn/ ；证券日报： http://www.zqrb.cn ； 证 券 时 报 ： https://www.stcn.com ； 经 济 参 考 报 ： http://www.jjckb.cn ； 金 融 时 报 ： https://www.financialnews.com ...

股票简称：必贝特 股票代码：688759 广州必贝特医药股份有限公司 BeBetter Med Inc. （住所：广州市高新技术产业开发区科学城崖鹰石路 25 号 A-3 栋第 八层 802 房） 首次公开发行股票科创板上市公告书 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 联席主承销商 （深圳市罗湖区红岭中路 1012 号国信证券大厦十六层至二十六层） 二〇二五年十月 广州必贝特医药股份有限公司（以下简称"必贝特"、"本公司"、"发行 人"、"公司"）股票将于 2025 年 10 月 28 日在上海证券交易所科创板上市。 根据《上海证券交易所科创板上市公司自律监管指引第 5 号——科创成长 层》，上市时未盈利的科创板公司，自上市之日起纳入科创成长层。截至本公告 披露日，必贝特尚未盈利，自上市之日起将纳入科创成长层。 普通投资者参与科创成长层股票或者存托凭证交易的，应当符合科创板投资 者适当性管理的要求，并按照上海证券交易所有关规定，在首次参与交易前以纸 面或者电子形式签署《科创成长层风险揭示书》，由证券公司充分告知相关风险。 本公司提醒投资者应充分了解股票市场风险及本 ...

广州必贝特医药股份有限公司 章程(草案) $$\Xi{\bf{\cal{O}}}\,{\bf{\underline{{{--}}}}}\,\nexleftarrow\nexists\,\nexists\,\exists\,{\bf{\cal{H}}}$$ and and of the same | 第一章 总则 | | --- | | 第二章 经营宗旨和范围 | | 第三章 取り | | 第一节 股份发行 . | | 第二节 股份增减和回购 | | 第三节 股份转让 . | | 第四章 股东和股东大会 | | 第一节 股东 . | | 第二节 股东大会的一般规定 | | 第三节 股东大会的召集 | | 第四节 股东大会的提案与通知 . | | 第五节 股东大会的召开 . | | 第六节 股东大会的表决和决议 . | | 第五章 董事会 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 28 | | 第一节 董事 . | | 第二节 董事会 | ...

本次股票发行后拟在科创板市场上市，该市场具有较高的投资风险。科创板公司具有研发 投入大、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投 资者应充分了解科创板市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 广州必贝特医药股份有限公司 BeBetter Med Inc. （广州市高新技术产业开发区科学城崖鹰石路 25 号 A-3 栋第八层 802 房） 首次公开发行股票并在科创板上市 招股说明书 保荐人（主承销商） （广东省深圳市福田区中心三路8号卓越时代广场（二期）北座） 联席主承销商 （深圳市罗湖区红岭中路 1012 号国信证券大厦十六层至二十六层） 广州必贝特医药股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策 ...

广州必贝特医药股份有限公司 首次公开发行股票并在科创板上市 发行结果公告 保荐人（主承销商）：中信证券股份有限公司 联席主承销商：国信证券股份有限公司 广州必贝特医药股份有限公司（以下简称"发行人"）首次公开发行人民币 普通股（A 股）并在科创板上市（以下简称"本次发行"）的申请已经上海证券 交易所（以下简称"上交所"）上市审核委员会审议通过，并已经中国证券监督 管理委员会同意注册（证监许可〔2025〕1645 号）。 发行人的股票简称为"必贝特"，扩位简称为"必贝特"，股票代码为"688759"。 中信证券股份有限公司（以下简称"中信证券"或"保荐人（主承销商）"） 担任本次发行的保荐人（主承销商），国信证券股份有限公司（以下简称"国信 证券"）担任本次发行的联席主承销商（中信证券、国信证券以下合称"联席主 承销商"或"主承销商"）。 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、 网下向符合条件的网下投资者询价配售（以下简称"网下发行"）、网上向持有 上海市场非限售 A 股股份和非限售存托凭证市值的社会公众投资者定价发行（以 下简称"网上发行"）相结合的方式进行。 发行人与联席主承销 ...

广州必贝特医药股份有限公司 首次公开发行股票并在科创板上市 招股说明书提示性公告 保荐人（主承销商）：中信证券股份有限公司 联席主承销商：国信证券股份有限公司 扫描二维码查阅公告全文 广州必贝特医药股份有限公司（以下简称"必贝特"、"发行人"或"公司"） 首次公开发行人民币普通股（以下简称"本次发行"）并在科创板上市的申请已 经上海证券交易所（以下简称"上交所"）上市审核委员会审议通过，并已经中 国证券监督管理委员会（以下简称"中国证监会"）同意注册（证监许可〔2025〕 1645 号）。《广州必贝特医药股份有限公司首次公开发行股票并在科创板上市招 股说明书》在上海证券交易所网站（http://www.sse.com.cn）和符合中国证监会 规 定 条 件 网 站 （ 上 海 证 券 报 ： https://www.cnstock.com ； 中 国 证 券 报 ： https://www.cs.com.cn/ ； 证 券 日 报 ： http://www.zqrb.cn ； 证 券 时 报 ： https://www.stcn.com ；经济参考报： http://www.jjckb.cn ； 金 融 时 ...